- Home
- CANF vs GLBZ Comparison
CANF vs GLBZ Comparison
Compare CANF & GLBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GLBZ
- Stock Information
- Founded
- CANF 1994
- GLBZ 1949
- Country
- CANF Israel
- GLBZ United States
- Employees
- CANF N/A
- GLBZ N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GLBZ Major Banks
- Sector
- CANF Health Care
- GLBZ Finance
- Exchange
- CANF Nasdaq
- GLBZ Nasdaq
- Market Cap
- CANF 14.4M
- GLBZ 13.2M
- IPO Year
- CANF N/A
- GLBZ N/A
- Fundamental
- Price
- CANF $1.95
- GLBZ $5.50
- Analyst Decision
- CANF Strong Buy
- GLBZ
- Analyst Count
- CANF 2
- GLBZ 0
- Target Price
- CANF $14.00
- GLBZ N/A
- AVG Volume (30 Days)
- CANF 120.6K
- GLBZ 6.6K
- Earning Date
- CANF 11-15-2024
- GLBZ 10-29-2024
- Dividend Yield
- CANF N/A
- GLBZ 7.19%
- EPS Growth
- CANF N/A
- GLBZ N/A
- EPS
- CANF N/A
- GLBZ 0.18
- Revenue
- CANF $667,000.00
- GLBZ $11,581,000.00
- Revenue This Year
- CANF $356.93
- GLBZ N/A
- Revenue Next Year
- CANF N/A
- GLBZ N/A
- P/E Ratio
- CANF N/A
- GLBZ $30.92
- Revenue Growth
- CANF N/A
- GLBZ N/A
- 52 Week Low
- CANF $1.81
- GLBZ $3.37
- 52 Week High
- CANF $4.69
- GLBZ $7.16
- Technical
- Relative Strength Index (RSI)
- CANF 33.53
- GLBZ 51.24
- Support Level
- CANF $1.87
- GLBZ $5.38
- Resistance Level
- CANF $2.08
- GLBZ $5.68
- Average True Range (ATR)
- CANF 0.16
- GLBZ 0.17
- MACD
- CANF 0.00
- GLBZ -0.05
- Stochastic Oscillator
- CANF 12.71
- GLBZ 19.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.